Eli Lilly agreed to acquire Curevo, a privately held, clinical-stage vaccine developer based in the Seattle area, the drugmaker announced on 26 May 2026. Curevo shareholders could receive up to $1.5 billion in cash, made up of an upfront payment and one further payment if a specified milestone is reached. Lilly did not disclose how the total splits between the two.
Curevo was one of three acquisitions Lilly announced the same day as it moves into infectious disease. The others were LimmaTech Biologics, for up to $780 million, and Vaccine Company, for up to $1.55 billion, bringing the combined value of the three deals to about $3.83 billion.
Each transaction is subject to customary closing conditions, including expiry of the waiting period under the US Hart-Scott-Rodino antitrust law. Lilly did not give an expected closing date.
What Curevo built
Curevo's lead product candidate is amezosvatein, an adjuvanted subunit vaccine to prevent shingles in adults. It does not use mRNA. Lilly said it was engineered with a next-generation synthetic adjuvant, the ingredient that boosts the immune response, to make the shot easier to tolerate.
That is the gap Curevo is aiming at. Lilly said the current standard of care for shingles prevention works, but its side effects can hold down vaccination rates and make people hesitant to return for the second dose, leaving many with reduced or no protection. Pharmaceutical Technology identified the incumbent as GSK's Shingrix.
In a head-to-head Phase 2 trial against the standard of care, amezosvatein matched the immune response on all primary endpoints and cut side effects such as activity-limiting fatigue, chills and injection-site pain by more than half, according to Lilly. Lilly also pointed to evidence linking shingles to a higher risk of stroke and shingles vaccination to lower dementia risk, arguing that a better-tolerated vaccine could widen protection across the population.
“These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences.”
The funding
Curevo closed a $110 million Series B in March 2025. Medicxi, a European biotech investor, led the round, joined by new investors OrbiMed, HBM Healthcare Investments and Sanofi Ventures. Existing backers RA Capital Management, Janus Henderson Investors, Adjuvant Capital and founding investor GC Biopharma also took part, according to Pulse 2.0.
The company said at the time that the money would extend its Phase 2 programme to 640 more participants, including adults over 70, to settle on a dose before Phase 3. Moncef Slaoui, the former chief scientific adviser to Operation Warp Speed, became board chair, and Medicxi partner Giovanni Mariggi and Tal Zaks, formerly Moderna's chief medical officer, joined the board. George Simeon is Curevo's chief executive.
HBM Healthcare Investments said it put $13.3 million into the Series B and holds about 4.8% of Curevo. It said the sale would lift its net asset value per share by about CHF 4.00 (about $5), or 1.4%. Curevo's total funding across all rounds and its headcount were not reported in the sources reviewed.
Why Lilly is buying
Daniel Skovronsky, Lilly's chief scientific and product officer and president of Lilly Research Laboratories, said the three acquisitions were meant to prevent disease at its source rather than treat its consequences. He cited evidence that common infections are linked to diseases that can appear years later, including neurological disease, cancer and infertility, and said rising antimicrobial resistance makes vaccines increasingly the only route to prevention for some bacterial infections.
LimmaTech is developing vaccines against bacteria including Staphylococcus aureus, with its lead programme in Phase 1. Vaccine Company is working on a nanoparticle platform and has a five-antigen Epstein-Barr virus candidate it describes as ready for Phase 1. Of the three, Curevo's shingles vaccine is the furthest along in the clinic.
Lilly's 2026 buying spree
Pharmaceutical Technology reported that the three vaccine developers were Lilly's eighth, ninth and tenth acquisitions of 2026. The largest so far was sleep drug developer Centessa, bought for $7.8 billion in January, and the company also agreed deals for Kelonia Therapeutics and Ajax Therapeutics. The publication linked the pace of deals to strong sales of Lilly's obesity and type 2 diabetes drugs.
Analysts at Citi described the vaccine agreements as a well-balanced entry into a new field, noting that each lead asset could offer a large market opportunity and validate its underlying platform, according to the same report. Lilly said it would decide on the accounting treatment after closing and reflect the deals in its results and guidance from then on.
